| 摘要 |
<p>New decaprenylamines having the general formula: (I) wherein R1 represents a hydrogen atom, a decaprenyl group, a lower alkyl group or a hydroxy-lower alkyl group, and R2 represents a lower alkyl or alkenyl group optionally substituted with at least one hydroxy, amino or alkylamino group, or a cycloalkyl group, and the pharmaceutically acceptable acid addition salts thereof, are prepared by (a) converting decaprenol of the formula: (II) into a corresponding halide or sulfonic acid ester which is thereafter reacted with a primary or secondary amino compound having the general formula: (III) wherein R1 and R2 have the aforesaid meanings, in the presence or absence of a base, to obtain the desired decaprenylamine of the formula (I), or (b) oxidizing decaprenol to a corresponding aldehyde which is then condensed with a primary amino compound having the general formula: H2N - R2 (III') wherein R2 has the aforesaid meanings, to form a corresponding imino compound which in turn is reduced to obtain a decaprenylamine of the formula (I) in which R1 is hydrogen and R2 has the aforesaid meanings. When a pharmaceutically acceptable acid addition salt is desired, the decaprenylamine of the formula (I) thus obtained is further reacted with a pharmaceutically acceptable acid to provide the desired salt. The decaprenylamines of the formula (I) are useful for controlling virus infection of vertebrate animals.</p> |
